136 related articles for article (PubMed ID: 8340363)
1. Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design.
Rutenber E; Fauman EB; Keenan RJ; Fong S; Furth PS; Ortiz de Montellano PR; Meng E; Kuntz ID; DeCamp DL; Salto R
J Biol Chem; 1993 Jul; 268(21):15343-6. PubMed ID: 8340363
[TBL] [Abstract][Full Text] [Related]
2. The crystal structures at 2.2-A resolution of hydroxyethylene-based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations.
Murthy KH; Winborne EL; Minnich MD; Culp JS; Debouck C
J Biol Chem; 1992 Nov; 267(32):22770-8. PubMed ID: 1429626
[TBL] [Abstract][Full Text] [Related]
3. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
[TBL] [Abstract][Full Text] [Related]
4. A novel nonpeptide HIV-1 protease inhibitor: elucidation of the binding mode and its application in the design of related analogs.
Lunney EA; Hagen SE; Domagala JM; Humblet C; Kosinski J; Tait BD; Warmus JS; Wilson M; Ferguson D; Hupe D
J Med Chem; 1994 Aug; 37(17):2664-77. PubMed ID: 8064795
[TBL] [Abstract][Full Text] [Related]
5. Calculation of relative differences in the binding free energies of HIV1 protease inhibitors: a thermodynamic cycle perturbation approach.
Reddy MR; Varney MD; Kalish V; Viswanadhan VN; Appelt K
J Med Chem; 1994 Apr; 37(8):1145-52. PubMed ID: 8164256
[TBL] [Abstract][Full Text] [Related]
6. Advances in automated docking applied to human immunodeficiency virus type 1 protease.
Miller MD; Sheridan RP; Kearsley SK; Underwood DJ
Methods Enzymol; 1994; 241():354-70. PubMed ID: 7854188
[No Abstract] [Full Text] [Related]
7. Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design.
Perryman AL; Lin JH; Andrew McCammon J
Chem Biol Drug Des; 2006 May; 67(5):336-45. PubMed ID: 16784458
[TBL] [Abstract][Full Text] [Related]
8. Insights from atomic-resolution X-ray structures of chemically synthesized HIV-1 protease in complex with inhibitors.
Johnson EC; Malito E; Shen Y; Pentelute B; Rich D; Florián J; Tang WJ; Kent SB
J Mol Biol; 2007 Oct; 373(3):573-86. PubMed ID: 17869270
[TBL] [Abstract][Full Text] [Related]
9. A check on rational drug design: crystal structure of a complex of human immunodeficiency virus type 1 protease with a novel gamma-turn mimetic inhibitor.
Hoog SS; Zhao B; Winborne E; Fisher S; Green DW; DesJarlais RL; Newlander KA; Callahan JF; Moore ML; Huffman WF
J Med Chem; 1995 Aug; 38(17):3246-52. PubMed ID: 7650677
[TBL] [Abstract][Full Text] [Related]
10. Neutron crystallography used to identify targets to improve HIV-1 protease inhibitor.
Hill R
Future Med Chem; 2013 Oct; 5(15):1705. PubMed ID: 24144407
[No Abstract] [Full Text] [Related]
11. Two solutions for the same problem: multiple binding modes of pyrrolidine-based HIV-1 protease inhibitors.
Blum A; Böttcher J; Dörr S; Heine A; Klebe G; Diederich WE
J Mol Biol; 2011 Jul; 410(4):745-55. PubMed ID: 21762812
[TBL] [Abstract][Full Text] [Related]
12. X-ray crystallographic studies of a series of penicillin-derived asymmetric inhibitors of HIV-1 protease.
Jhoti H; Singh OM; Weir MP; Cooke R; Murray-Rust P; Wonacott A
Biochemistry; 1994 Jul; 33(28):8417-27. PubMed ID: 8031777
[TBL] [Abstract][Full Text] [Related]
13. The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors.
Mulichak AM; Hui JO; Tomasselli AG; Heinrikson RL; Curry KA; Tomich CS; Thaisrivongs S; Sawyer TK; Watenpaugh KD
J Biol Chem; 1993 Jun; 268(18):13103-9. PubMed ID: 8514751
[TBL] [Abstract][Full Text] [Related]
14. Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease.
Kempf DJ
Methods Enzymol; 1994; 241():334-54. PubMed ID: 7854187
[No Abstract] [Full Text] [Related]
15. Inhibition of human immunodeficiency virus-1 protease by a C2-symmetric phosphinate. Synthesis and crystallographic analysis.
Abdel-Meguid SS; Zhao B; Murthy KH; Winborne E; Choi JK; DesJarlais RL; Minnich MD; Culp JS; Debouck C; Tomaszek TA
Biochemistry; 1993 Aug; 32(31):7972-80. PubMed ID: 8347601
[TBL] [Abstract][Full Text] [Related]
16. Structure-assisted design of nonpeptide human immunodeficiency virus-1 protease inhibitors.
Rosé JR; Craik CS
Am J Respir Crit Care Med; 1994 Dec; 150(6 Pt 2):S176-82. PubMed ID: 7952656
[TBL] [Abstract][Full Text] [Related]
17. New active HIV-1 protease inhibitors derived from 3-hexanol: conformation study of the free inhibitors in crystalline state and in complex with the enzyme.
Ziółkowska NE; Bujacz A; Randad RS; Erickson JW; Skálová T; Hašek J; Bujacz G
Chem Biol Drug Des; 2012 May; 79(5):798-809. PubMed ID: 22296826
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of a tethered dimer of HIV-1 proteinase complexed with an inhibitor.
Bhat TN; Baldwin ET; Liu B; Cheng YS; Erickson JW
Nat Struct Biol; 1994 Aug; 1(8):552-6. PubMed ID: 7664084
[TBL] [Abstract][Full Text] [Related]
19. Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir.
Chen X; Weber IT; Harrison RW
J Mol Model; 2004 Dec; 10(5-6):373-81. PubMed ID: 15597206
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyquinones are competitive non-peptide inhibitors of HIV-1 proteinase.
Brinkworth RI; Fairlie DP
Biochim Biophys Acta; 1995 Nov; 1253(1):5-8. PubMed ID: 7492599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
